Pharmacokinetic effects of vigabatrin on cerebrospinal fluid amino acids in humans.
A study was conducted to assess the impact of single dosing and different dosing intervals of vigabatrin [gamma vinyl GABA (GVG)] in 11 patients with drug-resistant complex partial seizures. Cerebrospinal fluid (CSF) concentrations of total GABA, free GABA, homocarnosine, homovanillic acid (HVA), GVG, and 5-hydroxyindolacetic acid were measured up to seven days after a single dose. GVG levels were maximal within 24 h, suggesting that GVG acts to inhibit GABA-transaminase, and may also increase biogenic amines.
Ben-Menachem
E
E
Department of Neurology, University of Gothenburg, Sahlgren Hospital, Sweden.
D000328:Adult; D000596:Amino Acids / Q000378:metabolism*; D000614:Aminocaproates / Q000008:administration & dosage*; D000927:Anticonvulsants / Q000008:administration & dosage*; D002555:Cerebrospinal Fluid / Q000187:drug effects / Q000378:metabolism*; D004833:Epilepsy, Temporal Lobe / Q000188:drug therapy* / Q000378:metabolism; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D020888:Vigabatrin; D005680:gamma-Aminobutyric Acid / Q000378:metabolism
D000596:Amino Acids; D000614:Aminocaproates; D000927:Anticonvulsants; D005680:gamma-Aminobutyric Acid; D020888:Vigabatrin